At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 14 enrolled
Drug / intervention
Molnupiravirdrug
Likely dose
Molnupiravir 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment
In Brief
A Phase 1 clinical trial evaluating Molnupiravir for Hepatic Impairment. Completed, enrolled 14 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of N-hydroxycytidine (NHC) following a single oral dose of molnupiravir in participants 18 to 75 years (inclusive) with moderate hepatic impairment and healthy matched controls.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Impairment
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedMay 2022
Enrollment StartJun 2022
Primary CompletionDec 2022
Study CompletionJan 2023
TodayJul 2026
First PostedMay 23, 2022
Enrollment StartJun 14, 2022
Primary CompletionDec 18, 2022
Study CompletionJan 5, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.1 years ago
Interventions
Molnupiravirdrug
Four 200 mg capsules administered orally as a single dose